Genes that regulate dopamine (DA) receptors may underlie the overactive DA system in schizophrenia.
Patients with schizophrenia may suffer from an over active dopamine (OA) system in the brain (Wyatt et al. 1989) , based on the observations that antipsychotic and neuroleptic medications block brain OA 02 receptors in direct relation to their clinical potencies (Seeman et aI. 1976) and that brain D2 receptors may be more numerous in schizophrenia (Seeman et aI. 1987; Wong et al. 1986 , but for a more extensive analysis and dis cussion, see Farde et aI. 1990 , 1992 .
The activity of the D2 receptor is normally moder ated by its link to the D1 receptor (Seeman et al. 1989 ).
schizophrenics had previously been found to have a reduced link between DA Dl and D2 receptors. The DJ receptor genes were amplified by the polymerase chain reaction, subcloned, and sequenced. Although three DNA polymorph isms were found, the deduced amino acid sequence of the DA Dl receptor was normal in these tissues. fNeuropsychopharmacology 8: [131] [132] [133] [134] [135] 1993] This D1-D2Iink, although present in control brain tis sues and in Parkinson's-diseased or Alzheimer-diseased brain tissues, is missing or reduced in schizophrenia brain tissue (Seeman et al. 1989 ). In addition, Memo et al. (1983) found D1-stimulated adenylate cyclase to be elevated in schizophrenia brain tissue.
These fmdings justify a search for a possible abnor mality in the gene for the human DA D1 receptor in schizophrenia. The recent cloning of this gene (Suna hara et al. 1990; Dearry et al. 1990; Zhou et al. 1990) permitted us to examine the D1 receptor sequence in schizophrenia. We report here that the amino acid se quence of the D1 receptor in schizophrenia was normal in seven subjects, but there were three apparent poly morphisms in the deoxyribonucleic acid (DNA) se quence.
MATERIALS AND METHODS

Tissues
Post mortem brain samples were obtained at autopsy from five patients who had schizophrenia, and from one control individual, as previously described (See-0893-133X/93/$6.00 man et al. 1987) . The tissues were obtained through the Canadian Brain Tissue Bank (Toronto) and the Lainz Hospital (Vienna). Tissues from schizophrenia Patients T751 and T708 had previously been found to have a re duced link between 01 and 02 receptors, being absent in T751 and reduced by 60% in T708 (Seeman et al. 1989 ). An additional two blood samples were obtained from two schizophrenic outpatients. The diagnosis of schizophrenia met the criteria of International ClassifIcation of Disease version 9 (World Health Or ganization 1979) for tissues from Vienna or DSM-III-R (American Psychiatric Association 1987) for cases from Toronto.
Genomic DNA Preparation
Genomic DNA was extracted from each tissue or blood sample (Ausubel et al. 1988) . The brain tissues (weigh ing 100 mg) were homogenized in 1.2 ml of 10 mmol/L Tris-HCl (pH 8) containing 0.1 mg/ml proteinase K, 100 mmol/L NaCl, 25 mmol/L ethylenediaminetetraacetic acid (EDTA) and 0.5% sodium dodecylsulfate (50S), followed by overnight incubation at 50°C. Proteins were removed using phenol and chloroform extraction. The genomic DNA was precipitated with ethanol and resuspended in 10 mmol/L Tris-EDT A buffer (pH 8) and stored at 4°C.
Genomic DNA from the blood samples was ex tracted by the method of Miller et al. (1988) . Briefly, 10 ml of blood was mixed with 10 mmollL Tris-HCl (pH 7.6) in 320 mmollL sucrose, 1% Triton X-lOO, 5 mmol/L MgCh to a fmal volume of 40 ml. After centrifugation at 3000 x g for 10 minutes at 4°C, the remaining leuko cytes were digested overnight with proteinase K (125 Ilg/ml) in 3 ml of nucleus-lysing buffer (400 mmollL NaCl, 2 mmollL EDTA, 0.5% 505, 10 mmol/L Tris-HCl, pH 8.2) at 37°C. Proteins were precipitated with 1 ml of 6 mollL NaCl. The DNA was precipitated with etha nol, dried, and dissolved in 500 III of 20 mmollL Tris EDTA buffer (pH 8) and stored at 4°C.
DNA Amplification by the Polymerase Chain Reaction
Genomic DNA was amplified in vitro by the polymer ase chain reaction (PCR) using Taq polymerase (Cetus, Norwalk, CT) with oligonucleotide primers 758 and 757 (Biotechnology Service Centre, Hospital for Sick Chil dren Research Institute, Toronto). Primer 758 was 5'-tac ggatccAAGCAATCTGGCTGTGCAAAGTGCTGC CTGGT-3', where the first 9 nucleotide bases (in lower case) encode a BamHI site, and where the other nucleo tides correspond to bases at positions -123 to -92 in the human DA 01 receptor sequence (Fig. 2) Figure 1 . Agarose gel electrophoresis of amplifIed products.
Thirty III of amplifIed DNA were run in 1% agarose gel and visualized by ethidium bromide (lllg/ml). Lane 1 shows size markers. Lanes 2 and 3 show PCR-amplifIed genomic DNA from control and schizophrenia individuals, respectively. The arrow indicates the 1.5 kb fragment that contains the entire DA D1 receptor gene.
ments}. Following 30 cycles, the samples were given an additional elongation period of 7 minutes at 72°e. An aliquot was removed and analyzed by gel electro phoresis in 1% low-melt agarose containing ethidium bromide.
Subcloning and Sequencing
The peR products were extracted in phenol and chloro form, precipitated with ethanol and digested with BamHI. The cloning vector plasmid pSP73 (Promega) was digested with BamHI for 40 minutes followed by 30-minute incubation period with alkaline phosphatase. The peR product and plasmid pSP73 were extracted from the 0.8% low-melt agarose gel following electrophore sis, mixed in the same tube in the presence of T4 DNA li gase, and incubated overnight at room temperature. Transformation was done under standard conditions using AG1 cells (Stratagene) as the host. The DA D1 gene was screened by digestion of the plasmid DNA (ex tracted from the colony) with BamHI, generating a frag ment of approximately 1.5 kb. The nucleotide sequence of the cloned fragment was obtained by the dideoxy chain termination method (Sanger et al. 1987) , using Se quenase V.2 (USB, Cleveland, OH).
RESULTS
The size of the D1 receptor gene fragment from control and schizophrenia samples were the same (Fig. 1) . Di deoxy sequencing confIrmed the fragments encoding the D1 receptor in both control and schizophrenia tis sues. There were three DNA polymorphisms (see Fig. 2 ).
I} The nucleotide at position -48 was an A in our earlier work on one human individual (Sunahara et a1. 1990) , as well as in one sample by Dearry et a1. (1990) and in another by Zhou et a1. (1990) . In patient T708, however, this nucleotide was a G. A total, therefore, of 10 humans had an A, and only one revealed a G.
2} Nucleotide 90 in all cases (except V433-88) re vealed an A to G change. This did not, however, alter the coded amino acid, leucine. Other groups (Dearry et al. 1990; Zhou et a1. 1990 ) also found a G. Thus, a total of nine humans have revealed a G with two ex hibiting an A.
3} Nucleotide 222 in all individuals had an A to C change, but this did not affect the coding of the amino acid, alanine.
DISCUSSION
The results indicate that the amino acid sequence of the DA D1 receptor from seven schizophrenic individuals 01 Receptors in Schizophrenia 133 was normal, but that there were three apparent poly morphisms in the DNA sequence.
Concerning the DNA polymorph isms, it should be noted that the Taq polymerase used in these experi ments has an error rate or base misincorporation rate of about 0.1%. Thus, it is possible that the apparent DNA polymorphisms may arise as a PCR-generated ar tifact. Although various types of PCR procedures may rule out such artifacts, at least two of the three poly morphisms were identical in more than one subject.
Tissues from schizophrenia Patients T751 and T708 had previously been found (Seeman et al. 1989) to have a reduced link between D1 and 02 (absent link in T751, and 60% reduction of the link in T708). These schizophrenia patients, however, revealed ONA se quences identical to control individuals.
Since the number of different samples tested here was small, the results do not rule out the existence of an abnormal amino acid sequence in the 01 dopamine receptor of different patients in a more extensive series of schizophrenia patients. For example, it may be esti mated statistically that studying only seven subjects is insufficient to rule out a relevant receptor mutation in many (perhaps one-third) of schizophrenic patients. A more rapid method for screening possible mutations in a larger series of tissues is to use PCR and denatur ing gradient gel electrophoresis (Sung et a1. 1991; Catalano et a1. 1991) .
Furthermore, the absence of any changes in the 01 receptor protein in these seven schizophrenia cases does not preclude possible 01 receptor abnormalities in schizophrenia, since there may be abnormalities in posttranslational processing of these receptors (phos phorylation and glycosylation, for example).
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